A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Active, not recruitingOBSERVATIONAL
Enrollment

4,970

Participants

Timeline

Start Date

May 31, 2007

Study Completion Date

June 30, 2038

Conditions
Crohn's DiseaseUlcerative ColitisIndeterminate ColitisInflammatory Bowel Diseases
Interventions
BIOLOGICAL

Anti TNF therapy including infliximab

Treatments will be prescribed according to investigator judgement.

DRUG

No Biologics

Treatments will be prescribed according to investigator judgement.

Trial Locations (62)

Unknown

Mobile

Phoenix

Los Angeles

Oakland

Sacramento

San Diego

San Francisco

Aurora

Hartford

New Haven

Gainesville

Miami

Orlando

Atlanta

Boise

Chicago

Lexington

New Orleans

Portland

Boston

Newton

Worcester

Detroit

Southfield

Minneapolis

Rochester

Boys Town

Las Vegas

Manchester

Mays Landing

Morristown

Brooklyn

Buffalo

Lake Success

Mineola

New York

Stony Brook

Syracuse

The Bronx

Williamsville

Chapel Hill

Durham

Oklahoma City

Danville

Philadelphia

Greenville

Knoxville

Memphis

Dallas

Fort Worth

San Antonio

Burlington

Charlottesville

Fairfax

Norfolk

Seattle

Madison

Milwaukee

Edmonton

Halifax

Burlington

Toronto

Sponsors
All Listed Sponsors
lead

Janssen Biotech, Inc.

INDUSTRY

NCT00606346 - A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease | Biotech Hunter | Biotech Hunter